<DOC>
	<DOCNO>NCT01064596</DOCNO>
	<brief_summary>After bariatric surgery , thromboembolics complication major cause mortality . However , obese patient , thromboprophylaxia controversy . Fondaparinux ' efficacy superior HBPM , good treatment population . Pharmacokinetics information Fondaparinux population rare .</brief_summary>
	<brief_title>Fondaparinux Population Pharmacokinetic Morbid Obese Patients Post-operatory Bariatric Surgery</brief_title>
	<detailed_description>We propose bicentric study cohort obese patient ( BMI &gt; 40 kg/m2 ) treat 1 day injection Fondaparinux 2.5 mg bypass surgery . Anti-Xa activity Fondaparinux measure 4 time hospitalisation patient realise pharmacokinetic modelisation Fondaparinux . Haemorrhage thromboembolics event collect .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Obesity , Morbid</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Age â‰¥ 18 year old require bariatric surgery require antithrombotics prophylaxis morbid obesity base BMI &gt; 40 kg/m2 sign inform consent form contraindication fondaparinux history heparin induce thrombopenia ( HIT ) platelets &lt; 100 G/l require effective antithrombotic treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>obesity</keyword>
	<keyword>fondaparinux</keyword>
	<keyword>surgery</keyword>
	<keyword>anti-Xa activity</keyword>
</DOC>